A photo of Sheila Angeles-Han, MD, MSc.

Sheila T. Angeles-Han, MD, MSc

  • Physician, Division of Rheumatology
  • Associate Professor, UC Department of Pediatrics
  • Assistant Professor, UC Department of Ophthalmology



The field of rheumatology presents a unique challenge because of the thought processes involved in making decisions and diagnoses. During my fellowship training and as part of obtaining my master’s degree, I discovered a profound lack of high-quality research studies in pediatric uveitis. Now, I dedicate my research to improving the visual outcomes of children with chronic, noninfectious uveitis using interventions that decrease vision loss and blindness.

In the past, there were no valid measures of uveitis outcomes, which led to my development of the only questionnaire that assesses vision-related function and quality of life in children with the condition. The Effects of Youngsters’ Eyesight on QOL (EYE-Q) is now part of clinical outcome measurements used to characterize the impact of uveitis on children’s lives.

Through my research, I identify risk factors for uveitis development, specifically in children with juvenile idiopathic arthritis. I accomplish this by discovering biomarkers in tears and by using genetic associations.

I work to standardize the approach clinicians use to evaluate uveitis outcomes, including assessments of the impact of uveitis on quality of life and functioning. This information then helps improve treatment outcomes.

Throughout my career, I have received several grants from organizations like Cincinnati Children’s Hospital Medical Center, the National Institutes of Health, and other ophthalmology and rheumatology foundations. In my continuing work, I lead initiatives to improve screening, monitoring and treatment of children with juvenile idiopathic arthritis and uveitis.

Locations (2)

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information


S100 Proteins, Cytokines, and Chemokines as Tear Biomarkers in Children with Juvenile Idiopathic Arthritis-associated Uveitis. Angeles-Han, ST; Miraldi Utz, V; Thornton, S; Schulert, G; Rodriguez-Smith, J; Kauffman, A; Sproles, A; Mwase, N; Hennard, T; Grom, A; et al. Ocular Immunology and Inflammation. 2021; 1-5.

Uveitis in Children and Adolescents. Chang, MH; Shantha, JG; Fondriest, JJ; Lo, MS; Angeles-Han, ST. Rheumatic Disease Clinics of North America. 2021; 47:619-641.

Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Kennedy, K; Moni, TT; Harrison, C; Larché, MJ; Levine, M; Sattui, SE; Semalulu, T; Foster, G; Surangiwala, S; Thabane, L; et al. The Lancet. Rheumatology. 2021; 3:e707-e714.

Challenges in pediatric uveitis: update on systemic management of pediatric noninfectious uveitis (NIU) and family perspective. Miraldi Utz, VA; Lerman, MA; Stahl, ED; Davidson, SL; Kassem, I; Jung, J; Levin, A; Catherine, C; Dehne, S; LaMattina, K; et al. Journal of AAPOS. 2021; 25.

Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis. Thomas, J; Kuthyar, S; Shantha, JG; Angeles-Han, ST; Yeh, S. 2021; 6.

Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis. Lovell, DJ; Huang, B; Chen, C; Angeles-Han, ST; Simon, TA; Brunner, HI. RMD Open. 2021; 7.

Comprehensive assessment of quality of life, functioning and mental health in children with juvenile idiopathic arthritis and non-infectious uveitis. McDonald, J; Cassedy, A; Altaye, M; Andringa, J; Cooper, AM; Drews-Botsch, C; Engelhard, G; Hennard, T; Holland, GN; Jenkins, K; et al. Arthritis Care and Research. 2021.

Ophthalmology perspectives on the management of juvenile idiopathic arthritis-associated uveitis: Eyeing the need for global, multidisciplinary collaborations. Angeles-Han, ST; Yeh, S. Clinical and Experimental Ophthalmology. 2021; 49:12-14.

Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST-Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial. Acharya, NR; Ebert, CD; Kelly, NK; Porco, TC; Ramanan, AV; Arnold, BF; Doan, T; Gonzales, JA; von Scheven, E; Angeles-Han, ST; et al. Trials. 2020; 21.

Assessing the validity and reliability of the Effects of Youngsters' Eyesight on Quality of Life (EYE-Q) questionnaire among children with uveitis. Cassedy, A; Altaye, M; Andringa, J; Cooper, AM; Drews-Botsch, C; Engelhard, G; Hennard, T; Holland, GN; Jenkins, K; Lambert, SR; et al. Arthritis Care and Research. 2020.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey